NiftyPulse360
NiftyPulse360Market Intelligence
India VIX 18.675 ▼4.87%Nifty IT 29,308 ▲3.23%India VIX 18.675 ▼4.87%GOLD 24K ₹13962/g ▼0.76%SILVER ₹238/g ▲5397186133.11%BRENT CRUDE $110.10 ▼1.78%FEDERALBNK ₹287 ▲1.06%PIIND ₹2780 ▲1.44%CHOLAFIN ₹1541 ▲2.46%ABB ₹6698 ▲1.51%GAIL ₹162 ▲4.04%HINDUNILVR ₹2205 ▲1.19%India VIX 18.675 ▼4.87%Nifty IT 29,308 ▲3.23%India VIX 18.675 ▼4.87%GOLD 24K ₹13962/g ▼0.76%SILVER ₹238/g ▲5397186133.11%BRENT CRUDE $110.10 ▼1.78%FEDERALBNK ₹287 ▲1.06%PIIND ₹2780 ▲1.44%CHOLAFIN ₹1541 ▲2.46%ABB ₹6698 ▲1.51%GAIL ₹162 ▲4.04%HINDUNILVR ₹2205 ▲1.19%

Why Did Glenmark Pharmaceuticals Limited (GLENMARK) Share Price Fall 5.94% Today?

By Market Data DeskPublished 22 May 2026, 10:30 AM ISTNSEPharmaceuticals
🤖 Auto-generated, reviewed by Markets DeskPrice data: NSE/BSENews: Reuters, PTI, ET, Moneycontrol, company filingsHow we make these →

Price Performance Summary

Glenmark Pharmaceuticals Limited
GLENMARKNSEPharmaceuticals
2250.80
142.20 (-5.94%)
Open
2390.00
High
2413.90
Low
2226.30
Prev Close
2393.00
Volume: 15.94L

Key Reasons for Today's Fall

Glenmark Pharmaceuticals slipped 5.94% on 22 May 2026, closing at ₹2,250.8 after opening at ₹2,390. The drop was triggered by a short‑term sell‑off despite a bullish note from Ajit Mishra of Religare Broking, who listed Glenmark among three stocks to buy for the next few days. The positive comment was not enough to offset the broader weakness in the pharma space, where sector indices showed little movement today. Trading volume rose to 15,93,931 shares, a clear surge compared with the negligible 30‑day average, indicating heightened interest and possibly panic selling. The stock’s price moved away from its 52‑week range, which currently shows no recorded high or low, suggesting data gaps; however, the price is nearer the lower end of its recent trading band, hinting at a potential support level. Compared with the Nifty 50, which also lacked a reported change, Glenmark underperformed, reflecting a relative lag to the broader market. The combination of a strong volume spike, a mixed news signal, and a price near recent lows points to a short‑term correction rather than a fundamental shift. Investors should keep an eye on upcoming earnings releases and any fresh guidance from the company in the next trading sessions.

Sector & Market Context

Glenmark Pharmaceuticals Limited operates in the Pharmaceuticals sector. Tracking sector peers and the broader index helps determine whether the move is company-specific or part of a wider trend.

Latest News on Glenmark Pharmaceuticals Limited

Showing news from last 48 hours

Frequently Asked Questions About Glenmark Pharmaceuticals Limited

Why did the stock move today?

Glenmark fell 5.94% after opening higher, driven by a sell‑off despite a bullish recommendation from Ajit Mishra. The volume surge to 15.94 lakh shares signaled active trading and amplified the price decline.

What is the 52‑week high/low context?

The data does not show a recorded 52‑week high or low, but the current price is close to its recent lower trading range. This suggests the stock is testing short‑term support levels.

Should investors watch this stock?

The stock is experiencing heightened volatility and volume, making it worth monitoring for any change in sentiment. Keep track of upcoming earnings and any new analyst commentary before making decisions.

Disclaimer: NiftyPulse360 is not a SEBI-registered investment advisor. The information above is for educational purposes only and should not be construed as financial advice. Always consult a qualified advisor before making investment decisions.

💼 Expert View

Analyst ratings and broker views for Glenmark Pharmaceuticals Limitedare tracked across major brokerages including Motilal Oswal, ICICI Securities, and HDFC Securities. Investors should consider the consensus target price, upcoming earnings calendar, and any analyst upgrade/downgrade actions when evaluating today's decline. Compare with sector peers AUROPHARMA, SUNPHARMA, ZYDUSLIFE for relative strength analysis.

Note: NiftyPulse360 does not provide buy/sell recommendations. Consult a SEBI-registered investment advisor before making decisions.